The importance of free fatty acids in the development of Type 2 diabetes

Diabetic Medicine

Volumn 24, Issue 9, 2007, Pages 934-945

  Wilding, J P H ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Epidemiology; Free fatty acids; Obesity; Peroxisome proliferator activated receptors; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BEZAFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; LIPID; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TESAGLITAZAR; TETRAHYDROLIPSTATIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; BARIATRIC SURGERY; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DIET; DISEASE ACTIVITY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EPIDEMIOLOGICAL DATA; ETHNICITY; EXERCISE; FATTY ACID BLOOD LEVEL; HEART FAILURE; HUMAN; IMMUNOMODULATION; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER TOXICITY; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROPHYLAXIS; REVIEW; RISK REDUCTION; SUBCUTANEOUS FAT; TOXICOLOGY; VISCERA; WEIGHT REDUCTION;

ADIPOSITY; ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FEMALE; HUMANS; MALE; OBESITY; PREVALENCE;

EID: 34548186474     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02186.x     Document Type: Review

References (136)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27:1047 1053.
2. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, 3-5 June, 1997. Geneva:World Health Organization, 1998.
3. Cameron AJ, Welborn TA, Zimmet PZ, Dunstan DW, Owen N, Salmon J et al. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003 178:427 432.
4. Katzmarzyk PT. The Canadian obesity epidemic: an historical perspective. Obes Res 2002 10:666 674.
5. Eckel RH, York DA, Rossner S, Hubbard V, Caterson I, St Jeor ST et al. Prevention Conference VII. Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004 110:2968 2975.
6. Dunstan DW, Zimmet PZ, Welborn TA, de Courten MP, Cameron AJ, Sicree RA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002 25:829 834.
7. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994 17:961 969.
8. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995 122:481 486.
9. Satman I, Yilmaz T, Sengul A, Salman S, Salman F, Uygur S et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish Diabetes Epidemiology Study (TURDEP). Diabetes Care 2002 25:1551 1556.
10. Bays H, SHIELD Study Group. BMI and frequency of diabetes, hypertension and dyslipidemia: comparison of SHIELD and NHANES data. NAASO Annual Meeting October 15-19 2005, Vancouver, British Columbia, Canada. Abstract 488-P.
11. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J Am Med Assoc 2003 289:76 79.
12. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002 25:1790 1794.
13. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001 161:1581 1586.
14. Modan M, Karasik A, Halkin H, Fuchs Z, Lusky A, Shitrit A et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension. Diabetologia 1986 29:82 89.
15. Everhart JE, Pettitt DJ, Bennett PH, Knowler WC. Duration of obesity increases the incidence of NIDDM. Diabetes 1992 41:235 240.
16. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999 22:1266 1272.
17. Dagenais GR, Auger P, Bogaty P, Gerstein H, Lonn E, Yi Q et al. Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. Can J Cardiol 2003 19:1387 1391.
18. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003 26:868 874.
19. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002 19:708 723.
20. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002 359:2072 2077.
21. Benjamin SM, Valdez R, Geiss LS, Rolke DB, Narayan KM. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 2003 26:645 649.
22. Lindahl B, Weinehall L, Asplund K, Hallmans G. Screening for impaired glucose tolerance. Results from a population-based study in 21057 individuals. Diabetes Care 1999 22:1988 1992.
23. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956 4:20 34.
24. Ohlson LO, Larsson B, Svardsudd K, Welin I, Eriksson H, Wilhelmsen L et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985 34:1055 1058.
25. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999 341:1097 1105.
26. Eliasson M, Lindahl B, Lundberg V, Stegmayr B. Diabetes and obesity in Northern Sweden: occurrence and risk factors for stroke and myocardial infarction. Scand J Public Health 2003 31:70 77.
27. Abate N, Chandalia M. The impact of ethnicity on type 2 diabetes. J Diabetes Complications 2003 17:39 58.
28. Daniel M, Rowley KG, McDermott R, Mylvaganam A Dea K. Diabetes incidence in an Australian aboriginal population. An 8-year follow-up study. Diabetes Care 1999 22:1993 1998.
29. Cassano PA, Rosner B, Vokonas PS, Weiss ST. Obesity and body fat distribution in relation to the incidence of non-insulin-dependent diabetes mellitus. A prospective cohort study of men in the normative aging study. Am J Epidemiol 1992 136:1474 1486.
30. Chen KT, Chen CJ, Gregg EW, Williamson DF, Narayan KM. High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic? Diabetes Res Clin Pract 1999 44:59 69.
31. Moon OR, Kim NS, Jang SM, Yoon TH, Kim SO. The relationship between body mass index and the prevalence of obesity-related diseases based on the 1995 National Health Interview Survey in Korea. Obes Rev 2002 3:191 196.
32. Resnick HE, Valsania P, Halter JB, Lin X. Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care 1998 21:1828 1835.
33. Ko GT, Chan JC, Chow CC, Yeung VT, Chan WB, So WY et al. Effects of obesity on the conversion from normal glucose tolerance to diabetes in Hong Kong Chinese. Obes Res 2004 12:889 895.
34. Ramachandran A, Snehalatha C, Viswanathan V, Viswanathan M, Haffner SM. Risk of non-insulin-dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract 1997 36:121 125.
35. Potts J, Simmons D. Sex and ethnic group differences in fat distribution in young United Kingdom South Asians and Europids. J Clin Epidemiol 1994 47:837 841.
36. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999 84:137 144.
37. Dudeja V, Misra A, Pandey RM, Devina G, Kumar G, Vikram NK. BMI does not accurately predict overweight in Asian Indians in northern India. Br J Nutr 2001 86:105 112.
38. Reaven GM. The fourth musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 1995 38:3 13.
39. Golay A, Felber JP, Jequier E, DeFronzo RA, Ferrannini E. Metabolic basis of obesity and non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1988 4:727 747.
40. Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the anti-hyperglycemic effect of metformin. Diabetes Care 1998 21:1301 1305.
41. Groop LC, De Bonadonna RCI, Prato S, Ratheiser K, Zyck K, Ferrannini E et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989 84:205 213.
42. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988 37:1020 1024.
43. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002 32:14 23.
44. Kooner JS, Baliga RR, Wilding J, Crook D, Packard CJ, Banks LM et al. Abdominal obesity, impaired non-esterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. Arterioscler Thromb Vasc Biol 1998 18:1021 1026.
45. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003 111:121 124.
46. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 1999 48:1836 1841.
47. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995 38:1213 1217.
48. Pankow JS, Duncan BB, Schmidt MI, Ballantyne CM, Couper DJ, Hoogeveen RC et al. Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care 2004 27:77 82.
49. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997 40:1101 1106.
50. Byrne CD, Maison P, Halsall D, Martensz N, Hales CN, Wareham NJ. Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome. Diabet Med 1999 16:1007 1015.
51. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004 113:1582 1588.
52. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989 83:1168 1173.
53. Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud'Homme D, Lupien PJ et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992 41:826 834.
54. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997 273:E425 E432.
55. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999 48:839 847.
56. Lemieux S, Prud'Homme D, Nadeau A, Tremblay A, Bouchard C, Despres JP. Seven-year changes in body fat and visceral adipose tissue in women. Association with indexes of plasma glucose-insulin homeostasis. Diabetes Care 1996 19:983 991.
57. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004 350:2549 2557.
58. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995 96:88 98.
59. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997 46:1579 1585.
60. Richelsen B, Pedersen SB, Moller-Pedersen T, Bak JF. Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism 1991 40:990 996.
61. Rebuffe-Scrive M, Andersson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intra-abdominal depots of non-obese men and women. Metabolism 1989 38:453 458.
62. Mauriege P, Galitzky J, Berlan M, Lafontan M. Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur J Clin Invest 1987 17:156 165.
63. Busetto L, Digito M, Dalla MP, Carraro R, Enzi G. Omental and epigastric adipose tissue lipolytic activity in human obesity. Effect of abdominal fat distribution and relationship with hyperinsulinemia. Horm Metab Res 1993 25:365 371.
64. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005 288:E454 E461.
65. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005 21:3 14.
66. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and post-receptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983 32:117 123.
67. Kurioka S, Murakami Y, Nishiki M, Sohmiya M, Koshimura K, Kato Y. Relationship between visceral fat accumulation and anti-lipolytic action of insulin in patients with type 2 diabetes mellitus. Endocr J 2002 49:459 464.
68. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkanen L, Selby J et al. Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996 45:742 748.
69. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr 1999 69:381 387.
70. Perry AC, Applegate EB, Jackson ML, Deprima S, Goldberg RB, Ross R et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. J Appl Physiol 2000 89:636 643.
71. Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 1996 45:1119 1124.
72. Tulloch-Reid MK, Hanson RL, Sebring NG, Reynolds JC, Premkumar A, Genovese DJ et al. Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in African Americans. Obes Res 2004 12:1352 1359.
73. Crespin SR, Greenough WB III., Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. J Clin Invest 1973 52:1979 1984.
74. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 1986 78:1648 1657.
75. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes 1999 48:1270 1274.
76. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005 54:1640 1648.
77. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963 1:785 789.
78. Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 2004 27:2253 2259.
79. Bronfman M, Morales MN, Orellana A. Diacylglycerol activation of protein kinase C is modulated by long-chain acyl-CoA. Biochem Biophys Res Commun 1988 152:987 992.
80. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P et al. Free fatty acids produce insulin resistance and activate the pro-inflammatory nuclear factor-κB pathway in rat liver. Diabetes 2005 54:3458 3465.
81. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002 283:E12 E19.
82. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995 44:1239 1242.
83. Boden G, Chen X, Iqbal N. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and non-diabetic subjects. Diabetes 1998 47:1609-1612.
84. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 1998 47:1613 1618.
85. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W et al. A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003 52:2461 2474.
86. Bonner-Weir S, Deery D, Leahy JL, Weir GC. Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 1989 38:49 53.
87. Zhou YP, Grill V. Long-term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995 80:1584 1590.
88. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002 23:201 229.
89. Chen NG, Reaven GM. Fatty acid inhibition of glucose-stimulated insulin secretion is enhanced in pancreatic islets from insulin-resistant rats. Metabolism 1999 48:1314 1317.
90. Jacqueminet S, Briaud I, Rouault C, Reach G, Poitout V. Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration. Metabolism 2000 49:532 536.
91. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002 51:1437 1442.
92. Liu RH, Mizuta M, Kurose T, Matsukura S. Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord 2002 26:318 326.
93. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998 47:1384 1391.
94. Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 2004 89:4649 4655.
95. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995 270:26746 26749.
96. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001 86:1930 1935.
97. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003 52:239 243.
98. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003 278:9073 9085.
99. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002 8:1288 1295.
100. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002 143:998 1007.
101. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999 100:2473 2476.
102. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001 103:1057 1063.
103. Benedetti G, Mingrone G, Marcoccia S, Benedetti M, Giancaterini A, Greco AV et al. Body composition and energy expenditure after weight loss following bariatric surgery. J Am Coll Nutr 2000 19:270 274.
104. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, Van Loan MD, Ali MR, Wolfe BM et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 2006 49:2552 2558.
105. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999 7:477 484.
106. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 351:2683 2693.
107. Krebs JD, Evans S, Cooney L, Mishra GD, Fruhbeck G, Finer N et al. Changes in risk factors for cardiovascular disease with body fat loss in obese women. Diabetes Obes Metab 2002 4:379 387.
108. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 2003 289:1799 1804.
109. Kriska AM, Pereira MA, Hanson RL, de Cou rten MP, Zimmet PZ, Alberti KG et al. Association of physical activity and serum insulin concentrations in two populations at high risk for type 2 diabetes but differing by BMI. Diabetes Care 2001 24:1175 1180.
110. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parik ka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 344:1343 1350.
111. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006 368:1673 1679.
112. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346:393 403.
113. Burke JP, Williams K, Narayan KM, Leibson C, Haffner SM, Stern MP. A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care 2003 26:1999 2004.
114. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004 27:33 40.
115. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27:155 161.
116. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002 51:3486 3491.
117. Jonkers IJ, Smelt AH, Hattori H, Scheek LM, van Gent T, de Man FH et al. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG. effects of bezafibrate therapy. J Lipid Res 2003 44:1462 1469.
118. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005 4:1 5.
119. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001 24:710 719.
120. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002 51:797 802.
121. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004 109:2197 2202.
122. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005 26:2032 2038.
123. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H et al. Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005 54:582 586.
124. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005 366:1849 1861.
125. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human pre-adipocyte differentiation. J Clin Invest 1997 100:3149 3153.
126. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005 54:880 885.
127. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55:517 522.
128. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002 51:2796 2803.
129. Xiang AH, Peters RK, Kjos SL, Goico J, Ochoa C, Marroquin A et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and β-cell function. J Clin Endocrinol Metab 2004 89:2846 2851.
130. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 54:1150 1156.
131. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 128:176 185.
132. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006 368:1096 1105.
133. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005 366:1279 1289.
134. Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same? Lancet 2006 368:1218 1219.
135. Ashcroft JS. Prevention of diabetes: lifestyle and metformin are the way forward. Br Med J 2006 333:918 919.
136. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. J Am Med Assoc 2005 294:2581 2586.